Travere Therapeutics Inc (NASDAQ: TVTX) kicked off on Friday, down -0.50% from the previous trading day, before settling in for the closing price of $21.86. Over the past 52 weeks, TVTX has traded in a range of $5.12-$22.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2.15% over the past five years. While this was happening, its average annual earnings per share was recorded -139.47%. With a float of $85.72 million, this company’s outstanding shares have now reached $87.03 million.
Let’s look at the performance matrix of the company that is accounted for 380 employees. In terms of profitability, gross margin is 84.29%, operating margin of -169.03%, and the pretax margin is -171.4%.
Travere Therapeutics Inc (TVTX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.31%, while institutional ownership is 98.55%. The most recent insider transaction that took place on Feb 06 ’25, was worth 220,000. Before that another transaction happened on Feb 03 ’25, when Company’s SENIOR VICE PRESIDENT, R&D sold 8,951 for $19.78, making the entire transaction worth $177,051. This insider now owns 95,719 shares in total.
Travere Therapeutics Inc (TVTX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -139.47% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Take a look at Travere Therapeutics Inc’s (TVTX) current performance indicators. Last quarter, stock had a quick ratio of 1.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.56, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -1.18 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc (NASDAQ: TVTX) saw its 5-day average volume 1.73 million, a positive change from its year-to-date volume of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 80.04%. Additionally, its Average True Range was 1.05.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 94.52%, which indicates a significant increase from 86.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.99% in the past 14 days, which was lower than the 56.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.92, while its 200-day Moving Average is $13.06. Nevertheless, the first resistance level for the watch stands at $22.17 in the near term. At $22.59, the stock is likely to face the second major resistance level. The third major resistance level sits at $22.93. If the price goes on to break the first support level at $21.41, it is likely to go to the next support level at $21.07. The third support level lies at $20.65 if the price breaches the second support level.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
The company with the Market Capitalisation of 1.89 billion has total of 78,050K Shares Outstanding. Its annual sales at the moment are 145,240 K in contrast with the sum of -111,400 K annual income. Company’s last quarter sales were recorded 62,900 K and last quarter income was -54,810 K.
